Role of mucolytics in the management of COPD
نویسنده
چکیده
There is, to date, no medical therapy that modifies the decline in lung function that occurs in COPD. As the disease becomes more severe, exacerbations of COPD become increasingly common, affecting patient quality of life and increasing health care costs. Mucolytic agents, through their actions on inflammatory and oxidative pathways, have potential benefits in COPD. This paper reviews the randomized controlled trial (RCT) evidence for the effectiveness of at least 2 months of daily therapy with oral mucolytics in COPD. Based on evidence from 26 RCTs, mucolytics reduce exacerbations by up to 0.8 exacerbations per year, with a greater effect in patients with more severe COPD. This effect appears to be of a similar magnitude to the reduction in exacerbations seen with tiotropium and inhaled corticosteroids (ICS), but RCTs that compared the agents would be required to confirm this. Mucolytics do not affect the rate of lung function decline, but they do not have any significant adverse effects. Mucolytic treatment should be considered in: patients with more severe COPD who have frequent or prolonged exacerbations; those who are repeatedly admitted to hospital; or in those patients with frequent exacerbations who are unable to take tiotropium or ICS.
منابع مشابه
Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy.
Mucolytics are medicines that modulate mucus production and decrease mucus viscosity. Their mucus thinning effects may improve mucociliary transport and thereby facilitate expectoration of mucus out of the distal bronchial tree [1]. Improved clearance and expectoration of mucus can prevent mucus plugging of small airways and may theoretically improve gas exchange and lessen the probability of p...
متن کاملPneumocystis jirovecii colonization in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is associated with a chronic inflammatory response in airways and lung parenchyma that results in significant morbidity and mortality worldwide. Cigarette smoking considered as an important risk factor plays a role in pathogenesis of disease. Pneumocystis jirovecii is an atypical opportunistic fungus that causes pneumonia in immunosuppressed host, al...
متن کاملRole of Clarithromycin in Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
The prevalence of chronic obstructive pulmonary disease (COPD) is increasing in under-developing and developing countries. As per current estimations, COPD will become the third leading cause of death globally, by 2030. Long-acting anti-cholinergic agents, β2-agonists, inhaled corticosteroids, antibiotics and mucolytics are few of the agents currently used in the treatment of COPD, which improv...
متن کاملMucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
BACKGROUND Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent exacerbations with an increase in volume and/or purulence of sputum and any therapy that reduced the number of exacerbations would be useful. There is a marked difference between countries in terms of the prescribing of mucolytics depending on whether or not they are perceived to ...
متن کامل